Hilgers, T. W. (2004). Chapter 86: Summary of NaProTECHNOLOGY Biomarkers. In The Medical and Surgical Practice of NaProTECHNOLOGY.
Hilgers TW. Chapter 86: Summary of NaProTECHNOLOGY Biomarkers. In: The Medical and Surgical Practice of NaProTECHNOLOGY. 2004.
Hilgers, T. W. "Chapter 86: Summary of NaProTECHNOLOGY Biomarkers." The Medical and Surgical Practice of NaProTECHNOLOGY, 2004.
For EndNote, Zotero or Mendeley:
License
Open-access status not yet checked.
Author affiliations
1 institution
Pope Paul VI Institute for the Study of Human Reproduction, Omaha, Nebraska.027jqx654
Linked to ROR, the Research Organization Registry
RRM Academy Synopsis
Limited mucus cycles were more common in infertility and miscarriage
A 2004 book chapter compares fertility charts across groups of women. Women with infertility had more limited mucus cycles than women with normal fertility. The same held for women with a history of miscarriage.
Key Findings
Charts from women with infertility showed limited mucus cycles more often than charts from women of normal fertility. The same held for women with a history of spontaneous abortion.
Premenstrual spotting was recorded in most women with infertility and in none of the normal fertility controls.
Most women in a group who had surgery for endometriosis charted a limited or dry mucus cycle.
Women with breast cancer showed more variation in the length of the post-Peak phase than normal fertility controls.
The chapter presents a working classification of ovulation disorders from serial ultrasound, including the luteinized unruptured follicle.
Interpretation
This chapter lines up charts by diagnosis: infertility, miscarriage, endometriosis, and breast cancer. Each group is matched against women with normal fertility. The pattern holds across groups. Less mucus, more spotting, and more change in cycle length go with reproductive and gynecologic disease. The findings support larger studies of mucus charting across these groups.
RRM Context
Restorative reproductive medicine is cycle-charting-informed. Clinicians read the cycle before they choose a treatment. In NaProTechnology, the Creighton Model System chart pairs daily mucus and bleeding signs with hormone and ultrasound findings. A limited mucus pattern or spotting is a clue. The clinician can trace it back to its cause.
Our editorial summary of this paper, not the article's abstract.
Abstract
This chapter consolidates, as a reference for the individual physician, the biomarkers important in NaProTECHNOLOGY that appear throughout the textbook. Its figures and tables are reproduced from earlier chapters and cover CrMS family planning charts, cervical mucus studies, targeted hormone evaluation and a working classification of ovulation disorders by serial ultrasound. Further sections present CrMS charts and related data for chronic discharges, pregnancy dating, stress, premenstrual syndrome, ovarian cysts, infertility, endometriosis, pelvic adhesions, spontaneous abortion, ectopic pregnancy, prematurity, preconceptional care, unusual bleeding, cancer and osteoporosis. A figure comparing breast cancer patients with normal controls reports decreased progesterone levels and mucus cycle scores and increased variability in the length of the post-Peak phase.
027jqx654 